Table 1.

Characteristics of included studies.

Studies	Samples		Median age (years)		Intervention regimens	Control regimens	Design	Phase	Median OS (months)	Median nPFS (months)
	W-T	W	W-T	W
Zhuang et al., 2013 [21]	23	31	60 (37–76)	63 (43–81)	WBRT 30 Gy/10 f plus erlotinib 150 mg/day	WBRT 30 Gy/10 f	Case-control	II	NR	NR
Lee et al., 2014 [22]	40	40	61.3 (48–75)	62.2 (41–73)	WBRT 20 Gy/5 f plus erlotinib 100 mg/day	WBRT 20 Gy/5 f + placebo	Randomized	II	3.4/2.9	1.6/1.6
Fu et al., 2012 [23]	38	123	A56 (38–77)		WBRT 30–40 Gy/2-3 W plus gefitinib 250 mg/day	WBRT 30–40 Gy/2-3 W	Case-control	NR	NR	NR
Wu et al., 2012 [24]	35	18	18–65		WBRT 40 Gy/20 f plus gefitinib 250 mg/day	WBRT 40 Gy/20 f	Randomized	NR	12.1/9.8	NR
Zhou et al., 2013 [25]	36	22	27–75		WBRT 40 Gy/20 f or 30 Gy/10 f plus gefitinib 250 mg/day or erlotinib 100 mg/day	WBRT 40 Gy/20 f or 30 Gy/10 f plus Taxol 135–175 mg/m2 d1 or Alimta 500 mg/m2 d1 or DDP 25 mg/m2 (d1–3)	Case-control	NR	23.2/7.1	NR
Pesce et al., 2012 [26]	16	43	57 (46–82)	63 (45–79)	WBRT 30 Gy/10 f plus gefitinib 250 mg/day	WBRT 30 Gy/10 f plus TMZ 75 mg/m2/day	Randomized	II	6.3/4.9	NR
Cai et al., 2013 [27]	65	92	66 (35–81)		WBRT 29.37~41.24 Gy, 3 Gy/d, 5 times/week plus gefitinib 250 mg/day or erlotinib 100 mg/day	WBRT 29.37~41.24 Gy, 3 Gy/d, 5 times/week	Case-control	NR	10.6/7.7	6/3.4

Notes. W-T: WBRT plus erlotinib/gefitinib; W: WBRT; NR: not reported; OS: overall survival; PFS: progression-free survival.